Suggestions
Carolin Barth
Chief Executive Officer
Carolin Barth is a prominent figure in the biotechnology sector, currently serving as the Chief Executive Officer (CEO) of MiroBio Ltd, a company focused on developing precision therapies for autoimmune diseases. She joined MiroBio in September 2021, bringing extensive experience from her previous role at Novartis, where she spent 17 years in various leadership positions, including global head of commercial and pipeline strategy for cell and gene therapies.124
Professional Background
- Education: Dr. Barth holds a medical degree and has clinical experience in hematology and oncology from the University Hospital Tübingen.
- Novartis: During her tenure at Novartis, she was instrumental in the development and commercialization of several significant therapies, including Cosentyx and Xolair. Her roles included global program head for chronic myeloid leukemia and rheumatology, as well as global head for dermatology and autoimmune diseases.124
- MiroBio: At MiroBio, she leads the company through its transition into clinical development, focusing on checkpoint agonist antibodies aimed at restoring immune balance in autoimmune disorders. Under her leadership, MiroBio's lead program, MB272, is anticipated to enter clinical trials.15
Leadership Style and Vision
Dr. Barth is recognized for her strategic mindset and ability to integrate research and commercial strategies effectively. She has expressed excitement about MiroBio's potential to deliver innovative treatments that could significantly improve patient outcomes in autoimmune diseases.12
Current Role
Since taking the helm at MiroBio, Dr. Barth has overseen key developments, including regulatory filings for clinical trials and the expansion of the company's pipeline. In August 2022, MiroBio was acquired by Gilead Sciences for $405 million, marking a significant milestone in her leadership journey.4
Additional Contributions
Dr. Barth also serves on various boards and is involved in advisory roles within the biotech community, further emphasizing her commitment to advancing healthcare solutions through innovative research and development strategies.34